Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Insulin Resistance 5 Hyperglycemia 3 Polycystic Ovary Syndrome 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Oligomenorrhea 1 Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Intracranial Aneurysm 1 Hypoglycemia 1 Hyperphagia 1 Hyperinsulinism 1 Hyperandrogenism 1 Hirsutism 1 Diabetes Mellitus, Type 2 1 Diabetes Mellitus, Type 1 1 Congenital Abnormalities 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

relacorilant 5 Metformin 5 Pioglitazone 4 Dipeptidyl-Peptidase IV Inhibitors 4 Sulfonylurea Compounds 3 Sitagliptin Phosphate 3 Resistance Training 3 saxagliptin 2 Vildagliptin 2 Sodium-Glucose Transporter 2 Inhibitors 2 Rosiglitazone 2 Nutritional Status 2 Glucagon-Like Peptide-1 Receptor Agonists 2 Blood Specimen Collection 2 voglibose 1 somapacitan 1 semaglutide 1 repaglinide 1 pembrolizumab 1 miglitol 1 metahexamide 1 meglitinide 1 mazdutide 1 glymidine 1 glisoxepide 1 gliquidone 1 glimepiride 1 glibornuride 1 empagliflozin 1 desaminopancreozymin octapeptide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Diabetes Mellitus, Type 2 × Insulin × Clear all

NCT07628556 2026-06-05

Antidiabetic Medications and Risk of Cancer

University of Pecs

74,799 enrolled

Diabetes Mellitus, Type 2, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡